Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis

Company Overview

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Key Stats

• Today's Range: $0.60 to $0.63
• 50-Day Range: $0.44 to $0.85
• 52-Week Range: $0.36 to $6.20
• Volume: 4,906 shs
• Average Volume: 1.77 million shs
• Market Capitalization: $3.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

Virpax Pharmaceuticals Stock Analysis - MarketRank™

Virpax Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Virpax Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Virpax Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.64% of the float of Virpax Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Virpax Pharmaceuticals has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Virpax Pharmaceuticals has recently decreased by 37.95%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Virpax Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Virpax Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.64% of the float of Virpax Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Virpax Pharmaceuticals has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Virpax Pharmaceuticals has recently decreased by 37.95%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.43

News Sentiment

Virpax Pharmaceuticals has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Virpax Pharmaceuticals this week, compared to 0 articles on an average week.

MarketBeat Follows

3 people have added Virpax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Virpax Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.20% of the stock of Virpax Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 32.23% of the stock of Virpax Pharmaceuticals is held by institutions.

VRPX Stock Analysis - Frequently Asked Questions

How have VRPX shares performed this year?

Virpax Pharmaceuticals' stock was trading at $3.2010 at the beginning of the year. Since then, VRPX shares have decreased by 80.3% and is now trading at $0.63.
View the best growth stocks for 2024 here.

When did Virpax Pharmaceuticals' stock split?

Virpax Pharmaceuticals's stock reverse split on the morning of Friday, March 1st 2024. The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Virpax Pharmaceuticals IPO?

Virpax Pharmaceuticals (VRPX) raised $15 million in an IPO on Wednesday, February 17th 2021. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

Who are Virpax Pharmaceuticals' major shareholders?

Top institutional shareholders of Virpax Pharmaceuticals include Garden State Investment Advisory Services LLC (1.17%). Insiders that own company stock include Anthony P Mack, Jerrold Sendrow and Eric Floyd.
View institutional ownership trends.

How do I buy shares of Virpax Pharmaceuticals?

Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Virpax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Virpax Pharmaceuticals investors own include AMC Entertainment (AMC), Daré Bioscience (DARE), Rallybio (RLYB), Mullen Automotive (MULN), Plug Power (PLUG), SNDL (SNDL) and SOS (SOS).

Company Calendar

• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VRPX
• CUSIP: N/A
• CIK: 1708331
• Web: www.virpaxpharma.com
• Phone: 610-727-4597
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.00
• High Stock Price Target: $3.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +376.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-15,190,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,554.34%
• Return on Assets: -338.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.13
• Quick Ratio: 0.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.42) per share
• Price / Book: -1.50

Miscellaneous

• Outstanding Shares: 4,890,000
• Free Float: 4,683,000
• Market Cap: $3.08 million
• Optionable: Not Optionable
• Beta: 1.09